Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
Stay up to date on the latest Foundation news and research.
Join Today!Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
Mutations in CRB1 are a relatively common cause of several inherited retinal degenerations, including: Leber congenital amaurosis (LCA) retinitis pigmentosa (RP), and macular dystrophy (MD).
CRB1 is a protein encoded by the CRB1 gene. CRB1 is essential for the structure of the outer limiting membrane, a band of structural support connecting photoreceptors and muller glia in the retina. CRB1 is also involved in controlling retinal cell numbers and cellular organization.
The exact onset, symptoms, and prognosis are often different for each person and depend on the disease they have been diagnosed with. In general, CRB1-associated LCA onsets at birth or in early childhood, whereas CRB1-associated RP onsets in the first two decades of life. CRB1-associated macular dystrophies tend to onset later. Researchers still do not understand why mutations in CRB1 can cause different diseases and variability in symptoms.
CRB1-associated disease is usually inherited in an autosomal recessive manner. This means a person must have two damaging CRB1 mutations to experience symptoms and disease. A person with CRB1-associated disease will not have any affected children unless their partner also carries a CRB1 mutation.
To date, more than 300 damaging mutations in CRB1 have been identified and linked to retinal disease.
There are many services and accommodative and assistive resources available to people and families with a CRB1-associated disease. Visit the Foundation’s Low Vision Resources page to learn about many of these resources. A low vision specialist can help recommend the resources that are right for you.
More information on living with CRB1-associated disease is in the Newly Diagnosed section of this website.
There are currently no clinical trials that are specifically focused on CRB1-associated disease, though there are some gene agnostic therapies in or nearing clinical trials that might be relevant to people with CRB1-associated retinal disease.
There are currently no treatments for CRB1-associated disease.
Next Section
Jump to Section
Nov 14, 2024
Strengthening research in retinal disease with record-breaking $19.8 million investment in innovative projects targeting vision loss worldwide.
The urgent mission of the Foundation Fighting Blindness is to drive the research that will provide preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. The Foundation is a beacon for those affected by these blinding diseases. Join the fight and help us accelerate our mission.
The Foundation Fighting Blindness meets all 20 Better Business Bureau Charity Standards.
Stay connected by receiving updates and communications from the Foundation!
Sign UpFoundation Fighting Blindness
Phone: (800) 683-5555
Donations can be mailed directly to:
Foundation Fighting Blindness, P.O. Box 45740, Baltimore, MD 21297-5740
© 2024 Foundation Fighting Blindness, All Rights Reserved. The Foundation Fighting Blindness is a qualified 501(c)(3) non-profit organization and all donations are tax deductible. EIN 23-7135845.